Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health Plc LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 250.00 112,390 16:29:51
Bid Price Offer Price High Price Low Price Open Price
250.00 253.00 254.50 242.00 246.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.84 -53.67 -12.55 707
Last Trade Time Trade Type Trade Size Trade Price Currency
17:14:20 O 1,671 250.013 GBX

Puretech Health (PRTC) Latest News

More Puretech Health News
Puretech Health Investors    Puretech Health Takeover Rumours

Puretech Health (PRTC) Discussions and Chat

Puretech Health Forums and Chat

Date Time Title Posts
30/9/202020:42PureTech Health - innovative healthcare786
22/7/201821:35PureTech Health (PRTC) One to Watch Monday -

Add a New Thread

Puretech Health (PRTC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Puretech Health trades in real-time

Puretech Health (PRTC) Top Chat Posts

Puretech Health Daily Update: Puretech Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 250p.
Puretech Health Plc has a 4 week average price of 233.50p and a 12 week average price of 233.50p.
The 1 year high share price is 339p while the 1 year low share price is currently 196p.
There are currently 282,623,821 shares in issue and the average daily traded volume is 210,398 shares. The market capitalisation of Puretech Health Plc is £706,559,552.50.
postme: #NCYT #BMN #MTR #SMS #PAY #PRTC #SLP #APP #CNCT Ten ‘magic formula’ stocks for investors looking for value and quality -
volvo: The bonuses will be deemed earned when the share price reflects that success imo.
justincosworth: Volvo, I don’t think any form of dividend would be wise. This company is focussed on growth. Distributing capital to fickle share holders will only undermine the business model of reinvesting profits in founding new entities and investing in early stage startups. There is a reason the largest companies are found in the US - they retain profits and invest in growth. The UK market is too dividend happy, and value is eroded at the expense of keeping short-term share holders happy. Let’s trust Daphne to allocate the capital wisely, and the share price will follow. Till then stay patient, lots of upside potential possibly to come.
zipstuck: This is what caused the rise in Karuna share price last week,
volvo: .....soon as Karuna gets de-risked, the share price here doubles. It goes from $100 a share to $200 a share. So many ups from here.
lendmeafiver: what the PRTC Share Price?
volvo: Agree and disagree. These types of companies are unique in the type of business plans they have. Karuna's success is the pay off point and if sold today would have netted Puretech best part of $800m....with another $130m knocking around. But there comes a point if the share price doesn't reflect this cash, what can you do. Shareholders want a return either in share price rise or dividends. Ideally both. Based on current cash burn, thats about 8 years funding. Too much cash on the books imo. Would Nasdaq like what they see. Of course they would and I would expect as announcement soon. Same as a IPO for Gelesis.
rambutan2: Likewise, don't see any chance of a special div - not something either biotechs or US management in general go in for. This listed on LSE because they couldn't get it away in the States, where there is no real history of incubator style cos. Here there are/have been a few ie IPO, MERC, BTG etc. Invesco (Henley) under the Mark Barnett regime were prepared to be an "anchor" shareholder (ala Woodford style) but required an LSE listing as PRTC went into the two huge UK income funds. However, as I've already explained above, the Invesco funds have shrunk by £ billions, both due to terrible performance - hence Mr Barnett's recent sacking - and consequent massive and continuing redemptions. As everything more liquid has either been sold or diminished in value, PRTC has risen to be the 3rd largest holding in both funds. This clearly is not a long term defendable position for the under pressure managers of the UK income/high income funds. And if redemptions continue at current rates, it is out of their hands. PRTC might now be in the ftse250, but one look at the number of Price Monitoring Extensions, tells you how difficult to trade in any size it actually is. Finally, PRTC doesn't easily fit into any category/mandate. What is it? An investment company or a biotech, or what? So no natural big insti fund buyers. And that goes for Nasdaq as well, hence I suspect the rather slow progress on the listing idea. Folks like it simple, and PRTC is complex. In any case, ramble over and it remains one of my largest (long term) holdings to which I'm happy to add on any dip to near 200p. htTps://
lendmeafiver: Further good news flow here today and KRTX looking solid, whilst the PRTC share price seems to be all over the place on minimal volume.
lendmeafiver: Agree. Surely given recent progress an ipo or other transaction at Gelesis has to be on the cards, will have a huge impact on the Prtc share price I expect.
Puretech Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Puretech H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201019 16:55:35